Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-07-21

Butterfly Network, Inc.

Butterfly Network sells handheld ultrasound devices, related cloud software, and partner licensing built on its semiconductor-based imaging chip platform.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable imaging can outgrow device-only economics

The product already works, and the addressable market is widening. The stock case depends on turning that footprint into recurring workflow and licensing revenue before larger imaging vendors make handheld ultrasound a bundled feature.

Analysis

Thesis

Butterfly can grow faster than a normal device company if cheaper AI makes handheld ultrasound routine across more care settings and Butterfly captures that expansion through probes, regulated workflow software, and embedded chip licensing before larger incumbents bundle the category.

Last Economy Alignment

Moderately positive: AI lowers training and workflow friction, which should expand ultrasound usage, and Butterfly still anchors value in hardware, trust, and integrations rather than a thin software wrapper.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.0x (from 5 most recent analyses)

Reasoning

The upside case is not that Butterfly becomes the ultrasound monopoly; it is that the market stops viewing it as only a handheld device maker. If the company converts more countries, proves recurring enterprise workflow value, and scales embedded partner revenue, it can support a much larger revenue base with a better mix. I still assume valuation discipline, so most of the return comes from execution, not multiple expansion.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The key risk is strategic timing, not product existence. Butterfly already has a real device and improving gross margins, but the stock needs recurring software, embedded licensing, and new care-channel proof to scale before incumbents narrow the handheld advantage. Regulatory gates and a still-rich starting valuation mean even good operating progress can produce only moderate equity returns if revenue mix does not improve fast enough.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company filing or press release appeared in the last 7-10 days; the setup is largely unchanged heading into second-quarter results.
No visible FedRAMP status upgrade or first Home and Community Care commercial win has surfaced yet, so the main proof gates remain open.
The most recent meaningful operating change is still the July 2 Brazil launch, which supports international TAM expansion but does not yet prove distributor velocity.

Forecast update

Slightly better return setup comes from a lower starting value and somewhat clearer international and embedded optionality, partly offset by unchanged proof gates.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.36

They control the probe, the imaging chip, and the software hooks that let ultrasound spread into more places as AI makes scanning easier. The risk is that bigger vendors turn handheld imaging into a cheap feature before Butterfly's recurring software and partner economics become strong enough to matter.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$7.06

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research